Research programme: antivirals - Pfizer

Drug Profile

Research programme: antivirals - Pfizer

Alternative Names: Antivirals research programme - Pfizer; Research programme: tricyclic non-nucleoside inhibitors - Pfizer; Tricyclic non-nucleoside inhibitors research programme - Pfizer

Latest Information Update: 23 Jul 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cytomegalovirus infections; Herpes simplex virus infections

Most Recent Events

  • 03 Oct 2000 Preclinical development for Cytomegalovirus infections in USA (Unknown route)
  • 03 Oct 2000 Preclinical development for Herpes simplex virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top